EPI-COVID-POP: COVID-19 Seroprevalence Study in French Guiana

Sponsor

Institut Pasteur (Industry)

Overall Status

Completed

CT.gov ID

NCT04490850

Collaborator

Institut Pasteur de la Guyane (Other), Laboratoire de biologie médicale, Institut Pasteur de la Guyane (Other), Laboratoire de biologie médicale de Kourou, French Guiana (Other), Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana (Other), Eurofins (Industry), Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana (Other)

3,541

Enrollment

Locations

Arm

14.3

Actual Duration (Months)

708.2

Patients Per Site

49.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Condition or Disease	Intervention/Treatment	Phase
Coronavirus Infection Severe Acute Respiratory Syndrome SARS-CoV Infection Covid19	Procedure: Blood sample	N/A

Detailed Description

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Study Design

Study Type:

Interventional

Actual Enrollment :

3541 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

COVID-19 Seroprevalence Study in French Guiana

Actual Study Start Date :

Jul 15, 2020

Actual Primary Completion Date :

Sep 24, 2021

Actual Study Completion Date :

Sep 24, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Participants Blood sample	Procedure: Blood sample Blood sample

Arm

Intervention/Treatment

Experimental: Participants

Blood sample

Procedure: Blood sample

Blood sample

Outcome Measures

Primary Outcome Measures

Measure of the COVID-19 immunity of the population [1 year]
The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies

Secondary Outcome Measures

Evaluation of the level of asymptomatic and pauci-symptomatic infections [1 year]
The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria:

Inability to consent
Person under guardianship or curatorship
Known pathology or a health problem contraindicated with the collect of blood sample.

Contacts and Locations

Locations

	Site	City	Country
1	Centre Hospitalier Andrée Rosemon	Cayenne	French Guiana
2	Laboratoire de biologie méicale, Institut Pasteur de la Guyane	Cayenne	French Guiana
3	Laboratoires Eurofins Guyane	Cayenne	French Guiana
4	Laboratoire de biologie médicale de Kourou	Kourou	French Guiana
5	Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni	Saint-Laurent du Maroni	French Guiana

Sponsors and Collaborators

Institut Pasteur
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Laboratoire de biologie médicale de Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
Eurofins
Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana